Recent studies suggest that targeted inhibition of the EGFR pathway using small-molecule EGFR inhibitors may offer a new systemic treatment option for MEC patients with CRTC1-MAML2 translocations (15). This evidence concerns the gene MAML2 and mucoepidermoid carcinoma.